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Transforming growth factor /3 (TGF(3),t originally isolated from platelets as a
25-kD peptide (1, 2), has been shown to be a product of other inflammatory cells,
includinglymphocytes (3, 4) and macrophages (5, 6), and to have potent immuno-
modulatory effects (7). Although five different forms ofTGFJ3 havenowbeen charac-
terized (1), only TGF01 and itshomologue,TGF02 (8, 9),have thus far been identified
in hemopoietic cells (6) . Each ofthesepeptides has been cloned, demonstrating that
TGF01 is encoded as a390 amino acid precursor (10), TGFs2 as a412 amino acid
precursor (11, 12), and that both have a signal peptide of 20-23 amino acids at the
NH2 terminus . The processed 112 amino acid chains ofthe two peptides share 72%
sequence homology and appear to bind equally well to TGFS class III receptors
(13), although TGFS1 binds with greater affinity than TGF02 to class I and II
receptors (14, 15) . Interestingly, lymphoid cells appear to possess only class I and
II TGF,6 receptors (16), although in vitro, lymphocyte and monocyte responses to
TGF01 and 02 appear comparable (6, 17, 18) . The secretion ofTGFa peptides
by lymphocytes and monocytes only afteractivation (3-6) implicates these polypep-
tides in the evolution ofimmunologic processes, and in recent studiesTGFR has
been identified in chronic inflammatory tissues (19-22), including the synovium of
rheumatoid arthritis patients (7, 22) and in experimentally induced arthritis in ro-
dents(22) . To define the role ofTGFS in such lesions, we injected natural or recom-
binant TGF0 directly into thejoint cavity of Lewis rats and monitored its effect
on cellular recruitment and activation, and on its potential modulation of patho-
genic effects . TGF01 and TGF02 were both found to induce synovial erythema,
swelling, andleukocyte infiltration . The infiltrating mononuclear cells, activated to
express growth factors, likely regulated the pronounced synovial hyperplasia that
wasapparent within 2-3 d . Basedon these observations, it appears thatTGF0, released
by platelets and inflammatory cells in the arthritic synovium, maydirectly contribute
to the events associated with inflammatory arthropathies .
Address correspondence to Dr. S .M . Wahl, NIDR, National Institutes ofHealth, Building 30, Room
326, Bethesda, MD 20892 .
Abbreviations used in this paper: AI, articular index ; i.a., intraarticular ;NM normal rat serum ; PEC,
peritoneal macrophages ; SCW, streptococcal cell wall; TGFS, transforming growth factor S.
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Materials and Methods
Reagents.
￿
Lyophilized, carrier-free, sterile TGF-(31 purified to homogeneity from bovine
bone (23) was reconstituted in 4 mM HCl and diluted in PBS (1 kg/25 JAI) just before injec-
tion. TGF-02, also purified to homogeneity from bovine bone (9), was lyophilized in the pres-
ence of rat serum albumin (RSA; 25 p,g RSA/1 ug TGFQ2), reconstituted in 10 mM HCI
(25 /~g/100 ld), and diluted to 1 ug/25 Al in PBS for injection. Recombinant TGF01 (rTGF
,Q1) (Genentech, So. San Francisco, CA) (109 ug/ml in 4 mM HCl) was also diluted in PBS
immediately before use. Corresponding vehicles for control injections in the contralateral
joints were 0.6 mM HCl in PBS for TGF01, 0.1% RSA in 1.6 mM HCl for TGF#2, and
1.5 mM HCl in PBS for rTGF01. All of these preparations had <0.2 ng/ml (limit of detec-
tion) of endotoxin as determined by the Limulus amebocyte lysate assay (24).
Intraarticular (i.a.) Administration of 7GF--(3.
￿
Specific pathogen-free 6-wk-old inbred Lewis
rats (Harlan-Sprague Dawley, Indianapolis, IN) were anesthetized and i.a. injections (25,l)
were given in the ankle joint, to the extensor surface of the talar-navicular joint, usinga 25-
gauge needle. Rats (n = 7-9) received 1 pg, unless otherwise indicated, ofTGF#1, TGFX32,
or rTGF01 in the right extremity and the appropriate vehicle (25 al) in the left extremity.
No evidence ofleakage around thejoint was apparent. The injection schedules are indicated
in the Results. Thejoints were clinically scored on an articular index (AI) scaleof0 (normal)
to 4 (severe inflammation) based on swelling, distortion, and redness of the joints (25).
LightandElectron Microscopic Analysis.
￿
At various intervals after administration ofTGF(3,
synovial tissues were obtained for histopathologic evaluation. In some experiments, animals
were anesthetized (chloralhydrate, 400 mg/kg, i.p.) and perfused with fixative solution con-
taining 2% glutaraldehyde, 2% formaldehyde, and 0.05% CaCIZ in a 0.1 M sodium caco-
dylate buffer, pH 7.4, for 10 min. Thejoints were then excised and immersed in fresh fixative
(22°C) for 2-3 h, washed, and stored at 4°C in 0.1 M cacodylate buffer with 7% sucrose.
The joints were demineralized in disodium EDTA at 4'C (26), trimmed into small pieces,
and washed again in cacodylate-sucrose buffer. After postfixation with 1% OS04, the tissues
were stained with 0.5% aqueous uranyl acetate, dehydrated in ethanol, and embedded in
Spurr epoxy resin. 1-/Am sections were stained with toluidine blue and examined by light
microscopy. Thin sections were stained with uranyl acetate and lead citrate for transmission
electron microscopy.
Thejoint tissues from additional animals were snap frozen in embedding medium (0. C. T.
compound; Miles Laboratories, Inc., Naperville, IL), sectioned (8 /Am) and stained with to-
luidine blue, hematoxylin and eosin, and Trichrome Masson (25). The slides were coded
and analyzed for evidence of an inflammatory reaction and/or other tissue abnormalities.
Additional sections were prepared for immunoperoxidase staining.
Identification ofMononuclear Cell Surface Antigens.
￿
T lymphocytes (0X19), monocytes/mac-
rophages (EDI), and Ia' cells (0X6) were identified using mAbs (Bioproducts for Science,
Indianapolis, IN) in combination with an immunoperoxidase-stainingtechnique (ABC Vec-
tastain Kit; Vector Laboratories, Inc., Burlingame, CA) (25). Control sections were incubated
without the primary antibody, with an irrelevant mAb or with mouse ascites fluid.
Peritoneal Macrophage and PBMC Cultures.
￿
Resident peritoneal macrophages (PEC) were
obtained from normal Lewis rats by peritoneal lavage with PBS. PBMC were isolated by
density gradient (Histopaque 1083; Sigma Chemical Co., St. Louis, MO) centrifugation of
heparinized blood obtained by intracardiac puncture.
Supernatants were generated by culturing 1 x 106 PBMC or PEC/ml in serum-free DME
(Gibco Laboratories, Grand Island, NY) containing 50 ug/ml gentamicin, 2 mM glutamine,
and 5 x 10-5 M 2-ME in 24-well plates (Costar, Cambridge, MA) in the presence or ab-
sence of TGF0 for 36 h at 37°C with 5'% COz.
Chemotaxis Assay.
￿
PBMC were suspended at 1 .1 x 106 monocytes/ml in Gey's balanced
salt solution (GBSS; National Institutes of Health Media Unit) containing 2 % BSA, antibi-
otics, and 0.015 M Hepes. The chemotaxis assay was carried out in 48-well microchamber
plates (Neuroprobe, Rockville, MD) with 5-p,m pore polycarbonate filters (27). TGFa1, TGF
/32, and rTGF-ail were diluted and assayed at 0-10 pg/ml. After a 90-min incubation at 37°C,
the polycarbonate filters were removed, fixed, and stained with Dif-Quik (American ScientificProducts, Stone Mountain, GA) and quantitated with an Optomax Image Analyzer (Op-
tomax, Hollis, NH). Chemotactic activity is defined as the mean (t SEM) number ofcells
that migrated through the 5-,um pores in three standard fields for each of triplicate filters.
Dermal fibroblasts were obtained and subcultured as reported (28). Fibroblast chemotaxis
was also determinedin 48-well microchamber plates using 8-Am PVP-free polycarbonate filters.
The fibroblasts (2.5 x 105/ml) were incubated for 150 min at 37°C, the filters removed,
stained, and counted as above.
IL-1 Assay.
￿
Cell-free supernatants (twofold dilutions)were assayed for IL-1 activity using
thymocytesfrom 6-8-wk-old C3H/HeJ mice as described (25). The cultures werepulsed with
0.5 ACi/well [3H]TdR (specific activity 1.9 Ci/mmol; Schwarz-Mann, Orangeburg, NY) for
the final 5 h of incubation and the incorporated radioactivity was determined. Data were
transformed into units by comparison to an IL-1 standard containing 100 Units/ml (Gen-
zyme Corp., Boston, MA).
TNFAssay.
￿
Cell-free supernatants were assayed for TNF by the L929 cytotoxicity assay
(29). rTNF (giftof Cetus Corp., San Francisco, CA) was used as the standard against which
the samples, diluted twofold, were compared.
Fibroblast Proliferation Assay.
￿
Primary synovial fibroblast cultures were established from
the synovium ofbacterial cell wall-injected Lewis rats (30) afterenzymatic dissociation with
collagenase (50 U/ml; Worthington Biochemical Corp., Freehold, NJ). Fibroblasts were cul-
tured at 5 x 104 cells/ml/well in 24-well flat-bottomed plates in DME alone (controls) or
DME containing 5% normal rat serum (NRS) and TGF01 or TGF/32 (0-20ng/ml) at 37°C
for 48 h. Additionally, fibroblasts were cultured in the presence of diluted cell-free superna-
tants derived from TGF$-stimulated monocytes. 4 h before harvest, the cultures were pulsed
with 1 uCi/ml [3H]TdR and proliferation was quantitated by the level of incorporation of
[3H]TdR in triplicate wells.
RNA Isolation andNorthern Analysis.
￿
Total RNA was isolated from 15 x 106 PEC cultured
for 4 h with media, TGF,Q1, TGF02, or rTGF0l (1-30 ng/ml) or from excised synovial tissues
by the acid guanidinium thiocyanate-phenol-chloroform extraction procedure (31). For
Northern blots, 5 hg total RNA was fractionated on 1 .0% agarose gels containing formalde-
hyde and transferred to nitrocellulose filters. The blots were prehybridized for 4 h and then
hybridized overnight with 31P-labeled cDNA probes. Probes included IL-10 cDNA (32), the
cDNA probe for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (33), and the
cDNA probe for human TGFal (10). The filters were washed and were exposed to Kodak
XAR film with intensifier screens at -70°C for 4-48 h.
Results
Clinical Manifestations of i.a. 71GF--0 Injection.
￿
Within 12-24 h after the initial in-
jection of 1 Ag of natural TGF#1 or its homologue, TGF-/32, significant swelling
and erythema became apparent in the treatedjoints. Two additionalinjections caused
further exacerbation of the response, which reached an Al of 3.6 t 0.5 for TGF01
and a maximum 4.0 for TGF#2 on the third day (Fig. 1). A similar administration
~-a TGF-BI
o-0 TGF-
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FIGURE 1.
￿
Induction ofjointswelling and erythemaby TGFS. Lewis
rats received 3 dailyi. a. injections of 1 tag ofTGF/31, TGF02, rTGF#l
or vehicle only. AI were determined at 24 h and dailythereafter. Data
represent the meanjointscoresofseventonine animals in each group.234
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ofrTGFS1 induced aparallel arthritic response achieving an Al of 4 within 2-3 d .
Since a maximalAI was obtained after three injections, treatmentwas stopped and
the course of the synovitis monitored for an additional 3 wk . As shown in Fig . 1,
the acuteswelling and erythema inducedby natural TGF01 and 02 declined within
7-10 d, whereas the response to the recombinant peptide persisted for >3 wk, with
some clinically apparent swelling evident >6 wk (datanot shown) . The mechanism
for the prolonged response to rTGF/31 is unclear, since the appropriate vehicle for
this preparation inducedno clinically apparent inflammatory response when injected
into thecontralateraljoint (Fig . 1), nor didthe vehicles forthe naturalTGF01 and (32 .
Since the rTGF01 induced a more pronounced clinical response than the natural
products, we compared the ability of various dilutions of the recombinant peptide
to cause clinically evident synovitis . As shown in Fig. 2, a single injection of 0 .01
or 0.1 wg rTGF(31 was ineffective in stimulating synovitis as compared with the 1.0
wg injection ofTGF01 . However, after a second injection at these lowerconcentra-
tions, significant articular indices were evident, even for 0.01 14g amounts . After the
third andfinal injection, theAI peaked andthen began to decline, reaching baseline
by 9 d (0.1 and0.01 ttg injections), except forthe 1.0 ttg injection regimen forwhich
the AI persisted after 9 d (see also Fig . 1) .
Histological Manifestations of 7UGF--J3 Injection .
￿
Because of the pronounced clinical
response in thejoints to the localadministration ofTGF(3, subsequent studies evalu-
ated the histopathogenesis of these lesions within the synovium . Whereas the syno-
vium ofnormal joints is represented by a thin layer of synovial lining cellsunderlaid
by looseadipose and connective tissue stroma (Fig . 3A), within hours after the local
administration ofTGF/31 or (32 the accumulation of inflammatory cells became ap-
parent in the synovial space (Fig . 3 B) and within the synovial tissue (Fig . 3 C) .
This recruitment ofinflammatory cells included some neutrophils with significantly
larger numbers ofmononuclear cells . Furthermore, many ofthemononuclear phago-
cytes appeared highly activated with large vacuoles and enlarged cytoplasm (Fig .
3 B). Interestingly, the cellular constituents oftheTGF0-induced lesions at24-48 h
were similar to what has been observed in synovial tissues 2-3 wk after the onset
of antigen-induced arthritis (25) .
FIGURE 2 .
￿
Dose-dependent synovitis
induced by recombinant TGF01 .
Lewis rats received three daily i.a . in-
jections of0.01, 0.1, or 1.0 pg of rTGF
01 . AI were determined on indicated
days .ALLEN ET AL .
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FIGURE 3 .
￿
Cellular infiltrate and synovial hyperplasia inducedbyTGR0 . Synovial tissues were
obtained from vehicle injected control joints (A) (original magnification, x25) or from TGF
O-injected joints at 24 h (B, C), 48 h (D), or 72 h (E). Arrows indicate mitotic figures (original
magnification, x4o) .
Associated with the accumulating mononuclear infiltrate was an increase in syno-
vial fibroblast-like cellsand an apparent angiogenic response byday 2-3 after initia-
tion ofTGF-a treatment (Fig. 3, D, E) . Synovial fibroblast accumulation was likely
due to recruitment because of the rapidity of the response, but was also associated
with a proliferative response of local cells as evidenced by the presence of mitotic
figures (Fig . 3 E) . After cessation of TGF-0 administration, the numbers of
mononuclear cellsgraduallydeclined in parallel with theclinically apparent decrease
in swelling and distortion of thejoints . Fibroplasia however, persisted, although at
reduced levels, and in the rTGF0-treated joints, enhanced cellularity persisted for
3-4wk. Thenature ofthe prolonged effect ofrTGF01 as compared with thenatural
peptides was not readily apparent . The appropriate vehicle-injected contralateral23 6
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joints were not characterized byacellular infiltrate, although occasional hemorrhage
due to injection trauma was seen .
During the evolution of the synovial inflammation and hyperplasia of synovial
fibroblast-like cells, no apparent evidence of erosion of the connective tissue struc-
tures occurred . In contrast, the synovial tissue demonstrated deposition ofnew con-
nective matrix by the recruited fibroblast population (Fig . 3, D, E) .
Identification ofMononuclearCellSubpopulations.
￿
To specifically define the infiltrating
mononuclear cells in the TGFa-injected synovium, the tissues were stained with
cell-specific mAbs by immunoperoxidase . As shown in Fig . 4, after a single TGF(3
injection, intense staining occurred with an antibody that recognizes rat mono-
cytes/macrophages(ED1) (34), indicating that themajority ofinfiltrating leukocytes
were of monocytic lineage . In contrast, there were few ED1 + cells in the thin syno-
vial lining of the vehicle only-treated joints (Fig . 4 A) . In addition, the majority
of these mononuclear phagocytes were Ia', indicative of in situ activation and
differentiation (Fig . 4 E) . Some Ia+ cells, which were also ED1- on sequential sec-
tions, were also seen in the normal synovium . A proportion of the infiltrating
mononuclear cells appeared to be lymphocytes as indicated by the levels of OX19
staining (Fig . 4,F) . No apparent differences in the relative numbers ofthese cellular
phenotypes were observed between the tissues injected with TGFal, TGFQ2, or
rTGF-/31 .
FIGURE 4. Characterization
of cellular infiltrates by mAbs .
Synovial sections obtained from
control (A, B, C) and after a
single i . a . injection ofTGF01
(D, E, F) were stained using an
immunoperoxidase technique
with mAbs directed at surface
antigens on macrophages(EDI)
(A, D), to Ia antigens (0X6) (B,
E), and on T lymphocytes
(0X19) (C, F) (original magni-
fication, x40).ALLEN ET AL.
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UltrastructuralAnalysis of 7LF-,l3-treatedSynovium .
￿
The impressive cellular response
to the local administration ofTGF0prompted us to further characterize these tissues
at the ultrastructural level . The normal synovial lining layer consists of 1 or 2 layers
ofrelatively flattened cells (Fig . 5A) . After i.a . injectionofTGF0, thelining showed
increased thickness and cellularity, with the cells appearing rounded and more ac-
FIGURE 5 .
￿
Ultrastructural analysis ofsynovium . (A) Vehicle-injected synovial tissue.Thejoint
space (JS) is lined by a layer ofone to two flattened cells . The underlying connective tissue con-
tains abundant collagen, scattered cells, andblood vessels. (B) 3 d after TGF01 administration .
The synovial lining layer is increased in thicknessand cellularity, the cells have rounded up and
appear more active . joint space (JS).238
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tive (Fig. 5 B) . Furthermore, the underlying matrix, which was relatively acellular
in the controls, became infiltrated with cells and the collagen bundles appeared dis-
rupted (Fig . 5, A, B) . As defined at the lightmicroscopic level andfurtherby immu-
nocytochemical analysis, the underlying tissue was infiltratedby many cells ofmono-
cytic lineage(Fig. 6, A, B, C) . Numerous examples were found ofan apparent intimate
relationship between these monocytic cells and fibroblast-like cells (Fig . 6, A, B),
as well as an association between mononuclear cells and mitotic cells, presumably
fibroblasts (Fig . 6 C) . Interestingly, an increased population of mast cells was ob-
served in the TGF/3-treated synovial tissues (Fig . 7).
FIGURE 6 .
￿
Mononuclearcells
in subsynovial connective tissue .
(A and B) 3 d after TGFS1 .
Numerous mononuclear cells
are seen in close association
with fibroblasts (FB) . Disrup-
tion ofthe subsynovial collage-
nous tissue is evident . joint
space US) . (C) 2 d after TGF
02 . Amononuclear cell (M) lies
adjacent to a fibroblast (FB) and
a mitotic cell (left).ALLEN ET AL .
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FIGURE 7 .
￿
Synovium 3 d after TGRft1 . Mast cells (MC) are frequently observed in the sub-
synovial connective tissue. (A and B) Mononuclear cells (M) are closely associated with fibro-
blasts (FB) . The collagenous tissue is disrupted .
Monocyte and Fibroblast Chemotaxis to TGF-f3 .
￿
The predominant effects of local ad-
ministration ofTGF9 to the synovium appeared to be monocyte recruitment and
activation, fibroblast recruitment and proliferation, and the deposition of extracel-
lular matrix . Our next series of experiments, therefore, focused on delineating in
vitro the mechanisms wherebyTGF0 might be mediating these tissue responses.
NaturalTGFf31, recently shown to be a potent chemoattractant for human periph-
eral blood monocytes (35, 36)was assayed for its ability to induce rat monocyte-mac-
rophage chemotaxis in an in vitro assay in parallel with TGFfl2 and the recom-
binant form ofTGFf31. TGFfl1, whethernatural or recombinant, inducedperipheral
blood monocyte (Fig . 8) and peritoneal macrophage (data not shown) chemotaxis
at 0.1 pg/ml . Furthermore, TGFX82, not previously tested for chemotactic activity,
induced a parallel response in the in vitro assay, consistent with its in vivo ability
to initiate monocyte recruitment into the synovium . As previously shownforhuman
fibroblasts (37), TGFf3-stimulated rodent fibroblast chemotaxis at femtomolar con-
centrations in an in vitro assay (Fig . 9) .240
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FIGURE 8 .
￿
Monocyte chemotactic activity ofTGF-(3 .
Rat peripheral bloodmonocytes (1 .1 x 106/ml) were as-
sayed for their ability to respond to TGFX41, TGF02,
and rTGF-01 at the indicated concentrations . The data
represent themean number of monocytes that migrated
in three fields for triplicate filters (nine determinations/
point) . Standard errors were routinely <10% of the
mean and data are representative offour experiments .
FIGURE 9 .
￿
Fibroblast chemotaxis toTGF0 . Dermal fibro-
blasts (2 .5 x 10 5/ml) were assayed in vitro for chemotactic
responsiveness toTGFsl at the indicated concentrations .
Data represent the mean t SEM fibroblasts per field for
triplicate filters .
Direct andIndirect Effects ofTGF-0on Fibroblast Proliferation.
￿
In addition to the recruit-
ment of fibroblasts into the synovium, the increased fibroblast population was also
attributed to proliferation as evidencedby the increased frequency ofmitotic figures
(Figs . 3 E and 6 C) . To determine whetherTGF(3 was directly mitogenic for syno-
vial fibroblasts, fibroblasts were cultured in the presence or absence ofTGFa and
proliferation monitored by incorporation of [3H]TdR into DNA (Table I) . The ad-
dition ofTGF-0to serum-free cultures offibroblastsdidnotinduce fibroblast prolifer-
ation and furthermore, the addition ofTGF-0 to proliferating fibroblasts (NRS-in-
duced) often suppressed the proliferative response . These data suggested that the
TGF/3-mediated fibroblast proliferative response in vivo mightbe mediated indirectly,
possibly through induction of monocyte growth factor production . In fact, TGFR
added to monocyte cultures stimulated these cells to release products capable of
stimulating fibroblast proliferation (Table I) .
Induction ofIL-1 Production by TGF-0In Vitro and In Vioo .
￿
One monocyte product
that can influence fibroblast growth is IL-1, and therefore we evaluated the effects
ofTGF(3 on the induction of IL-1 . Messenger RNA was obtained from PEC ex-ALLEN ET AL.
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TABLE I
Direct and Indirect Efects of TGF,6 on Rat Synovial
Fibroblast Proliferation In Vitro
' Synovial fibroblasts (5 x 104/ml) were cultured without (DME) or with 5%
NRS to which was added 0-20 ng/ml TGF-#1.
x Fibroblasts were cultured in the presence of cell-free supernatants obtained
from rat monocytes that had been stimulated for 36 h with 0-20 ng/ml TGF-
01 or TGF-p2 .
5 After 48 h, the fibroblast cultures were pulsed 4 h with [3H]TdR and evalu-
ated for incorporation of [3H]TdR into DNA. Data are the mean of tripli-
cate cultures from a representative experiment (n = 4).
posed to TGF-#1 or ,82 in vitro and probed with a cDNA probe for IL-1/3 (Fig. 10
A). After 4 h, IL-1/3 steady-state mRNA levels were elevated in TGF-a1- or TGF-
(32-treated cell cultures. The induction of ILl-0 mRNA was concentration depen-
dent with augmentation at 1 ng/ml and increasing mRNA levels at higher concen-
trations. Constitutively expressed GAPDH levels were not altered by TGF/3.
In parallel cultures, 36-h supernatants were assayed for IL-1 bioactivity (Fig. 10
B). At 1 ng/ml TGF-01 or TGFfl2, IL-1 could bedetected in themonocyte superna-
tantswithincreasedlevels at 10-20ng/mlTGF#. Aliquots ofthese culture superna-
tants were also assayed for TNF, another monocyte product with pleiotropic effects
in inflammation and repair. A similar concentration-dependent induction ofTNF
was observed in response toeither TGFa1 or TGF02 (data not shown), indicating
that TGF(3 is an effective inducer ofIL-1, TNF, andlikely other monocyte-derived
growth factors (6).
Because ofthe ability ofTGFflto stimulate monocytes to produce growth factors
such as IL-1 in vitro, weprocessed synovial tissue obtainedafter TGFa administra-
tion to determine whether TGFP was similarly active in vivo. As demonstrated in
Fig. 11, TGF,6 not only was an effective inducer ofIL-lei message in vitro, but also
Addition to
fibroblast culture Amount
Fibroblast
proliferation
([3H]TdR incorporation)
ng/ml cpm
DME + TGF-01 ` 0 6975
10 681
20 363
NRS + TGF-01 0 38,409
0.1 30,381
1 25,396
10 19,759
20 19,412
Monot 0 3,500
Monos + TGF-011 1 6,825
5 20,430
10 16,930
20 14,380
Monos + TGF-02t 1 20,395
5 13,506
10 5,735
20 5,456242
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FIGURE 10 .
￿
Induction ofIL-1 byTGF-(3 . (A) RNA
was isolated from peritoneal macrophages after 4 h
incubation with the indicated concentrations ofTGF
01 orTGF02 . Afterextraction, themRNA was ana-
lyzed by RNAhybridization with 32P-labeled IL-10
and GAPDH probes. (B) Peritoneal macrophages
were cultured at 106/ml in the presence or absence
of 1-20 ng/ml TGF01 orTGFS2. Cell-free super-
natants were harvested at 36hand assayed for IL-1
levels in the thymocyte costimulator assay. Units were
determinedby comparison witha standard curve with
100 U/ml IL-1 .
in vivo . Synovial tissue obtained 24 h after a single injection ofTGFR, which is
characterized by an infiltrate of activated (Ia') monocytic cells, expressed sig-
nificantly elevated steady-state levels of IL-1/3. Furthermore, mRNA levels ofTGF
(31 were also elevated in these tissues indicating autoinduction ofTGF0 . In addition
to the 2.4-kbmRNA ofTGF0, a recently identified 1 .9-kb transcript (38) was also
apparent in theTGF/3-injected synovial tissues, but not in the control synovium .
Discussion
The potential ofTGF0 to initiate synovial inflammation wasexamined by direct
injection of recombinant or natural TGF,61 or natural TGFa2 into the synovial
spaceofrathind anklejoints . Each form ofTGF0 rapidlyinducedaprofound syno-
vitis . Administration of as little as 20 ngrTGF01 initiated an inflammatory response
in the synovium . Early events included edema and leukocyte infiltration . Within
24hafter the first injection, mononuclear cellswere thedominant infiltrating inflam-
matory cell and immunohistochemical analysis indicated that they were primarily
Ia+ macrophages . Lesser numbers of T lymphocytes (0X19+) were detected . In-
creased cellularity of thesynovial lininglayerandfibroblast proliferation in the syno-
vial connective tissue were also apparent, andexpansion ofthe fibroblast population
and deposition of collagen continued over the entire period of peptide administra-
tion . At the apex (days 3-4) of the response, the formation of new capillaries wasALLEN ET AL .
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FIGURE 11 .
￿
Induction of IL-1# and TGF01 gene ex-
pression in synovium byTGFS. RNAwas isolated from
synovial tissue 24 h after a single i.a. injection ofTGFS
or vehicle . After extraction, the mRNA was analyzed
by RNA hybridization with 32P-labeled IL-1# and
TGF0I .
discernable. Both the mononuclear cell infiltration and the associated fibrosis were
reversible when i.a. injection ofTGFR was discontinued .
The complement of events induced by TGF0 was remarkable in its complexity
and diversity . Some, but not all, of the events can be ascribed to the direct activities
ofTGF0. For example, TGFS has been shown to be approximately three orders
of magnitude more potent than C5a as a chemoattractant for human monocytes
(35, 36), and as shown in the present study, TGFal, TGF02, and rTGF-(31 are also
chemotactic for rat monocytes. Thus, it appears likely that the mononuclear cell
infiltration seen in the synovium after i.a . injection ofTGFa largely reflects the
direct chemoattraction of monocytes and/or tissue macrophages by these peptides .
However, the possibility thatTGF9 might also induce additional chemotacticsignals
in vivo cannot be excluded . AlthoughTGFa has not been shown to be chemotactic
forTlymphocytes, the appearance ofT cells afterTGF(3 administration may indi-
cate the induction oflymphocyte chemoattractants such as IL-8 (39). Furthermore,
TGFS is directly chemotactic for fibroblasts (37) (Fig. 9) that increase in number
soon after TGF0 administration .
Other sequelae of i.a. TGFS cannot as readily be attributed to direct activity of
this cytokine . For example, fibroblast and endothelial cell proliferation is inhibited,
not promoted, by TGF0 in culture (reviewed in reference 1) . It seems probable,
therefore, that other signals, induced in situ by TGFS, may also play important
roles in the development ofTGFQ-induced synovial pathology. In this regard, it
has been recently reported that TGF01 and -02, at picomolar concentrations, in-
ducehuman monocytes to express several cytokines including IL-1/3, TNFa, platelet-
derived growth factor (PDGF), and basic fibroblast growth factor (bFGF) (6). In
the present study, we report that whereas TGF01 and TGF02 were not directly
mitogenic forsynovial fibroblasts, supernatants from TGFail- andTGFR2-stimu-
lated rat monocyte/macrophages did stimulate synovial fibroblast growth. These su-
pernatants contained significant levels ofIL-10andTNFa, and Northern blot analysis
demonstrated induction ofthe specificmRNA for IL-1/3. Consistent with this in vitro244
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observation was the elevation of IL-1/3 mRNA in the synovial tissue within 24 h
afterTGF(3 administration. Furthermore, these synovial tissues expressed increased
message levels for TGFX31, implicating an autoinduction of this peptide that may
further promote mononuclear cell recruitment and activation. Of interest is the
identification of the recently described 1.9-kb species of the TGF01 mRNA, the
function of which is unknown, but which has been linked to conditions of tissue
injury and inflammation (20, 38).
Several studies have documented that TGF-/3 promotes connective tissue matrix
synthesis by fibroblasts in vitro and in vivo. However, induction ofmonokine syn-
thesis by TGF0 may also contribute to regulation offibroblast matrix component
synthesis (reviewedin reference 1). In this regard, analysis ofthe mRNAfromTGF-
0-injected synovium revealed a marked increasein typeIprocollagenmRNA(Man-
they, C., unpublished observation) consistent with the morphological identification
of matrix deposition in these tissues. TGF(3 also suppresses the expression ofpro-
teases while promoting the synthesis ofprotease inhibitors (40) contributing to the
profibrotic influence of this peptide.
It is noteworthy that in contrast to the pannus invasion and destruction of carti-
lage andbone that is characteristic ofstreptococcalcell wall (SCW)-induced arthritis
in this rat model, the synovitis induced by TGF0 eventually resolves with no evi-
dence of permanent pathologic alterations ofthe joint. However, the transient na-
ture of the TGF(3 stimulus administered in these studies may not be reflective of
the chroniclesions in antigen-induced arthritis and thecontinued presence ofTGF0
and other cytokines that promote pannus formation and tissue erosion. Thus, al-
though TGF-0 may be a key mediator ofthe events associated with SCW-induced
arthritis, we cannot determine in these studies whether it is a causative factor in
joint destruction. Intriguing indirect support fora protective role forTGF(3in SCW-
induced arthritis is the suggestion that retinoids, which are effective in suppressing
SCW-induced joint destruction (41; Allen, J. B., H. L. Wong, G. L. Costa, and
S. M. Wahl, manuscript in preparation), may exert some oftheir biological actions
throughthe induction ofTGF0(1). TGF0 hasbeen identified notonly inthe tissues,
but in the synovial effusions ofpatientswith rheumatoid arthritis (18, 22, 42). Thus,
the contribution of TGF-/3 to the pathogenesis and/or regulation of this disease is
as yet speculative, since the potent immunosuppressive actions ofTGF0 (7), cou-
pled with its ability to promote tissue healing (43), suggest that it may be beneficial,
whereas the ability ofTGF9to promote inflammation through its effects on mono-
nuclear phagocytes (7) implicates this peptide as a pathogenic factor.
Summary
Afterintraarticularinjection ofTGF(31 orTGF(32, marked swelling and erythema
of the injected joints were apparent within 12-24 h. On a scale of 0 to 4, by day
3, the TGF-R-treated joints had articular indices (AI) of 3.6 t 0.5 to 4.0 t 0.0
compared with no response for the vehicle-injected contralateraljoints. Histopatho-
logic evaluation revealed a predominantly mononuclear phagocyte infiltrate with
some neutrophils andT lymphocytes, consistent with active inflammation. The mono-
cyticpatternofleukocyteinfiltration at 2-3 dwas comparable tothatseen in animals
with antigen-induced arthritisafter2-3 wk. Extensive synovialfibroblast hyperplasiaALLEN ET AL.
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became apparent within 48 h, likely as a result ofTGF(3 induction of growth factor
synthesis by the accumulating monocytes. TGF(32, a homologue of TGF(31, was
found to induce a similar level of synovitis and synovial hyperplasia consistent with
its parallel monocyte and fibroblast chemotactic properties and ability to induce tran-
scription and translation of monocyte/macrophage-derived growth factors. These
data suggest that TGF0, released by platelets and activated inflammatory cells, may
play a direct role in leukocyte recruitment and activation in arthritic and other chronic
inflammatory lesions.
We are grateful to Glenn Welch and Suanne Dougherty for expert assistance, to Mary Campbell
and Sarah Smith formanuscript preparation, to Drs. H. M. Shepard and D. Goeddel (Genen-
tech, Inc., South San Francisco, CA) for recombinant TGF01 and the TGF(31 cDNA probe,
and to Dr. Don Carter (The Upjohn Company, Kalamazoo, MI) for the IL-1(3 cDNA probe.
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